Chimeric Antigen Receptor T Cells in Multiple Myeloma.

BCMA BiTEs CAR-T GPRC5D Multiple myeloma

Journal

Hematology/oncology clinics of North America
ISSN: 1558-1977
Titre abrégé: Hematol Oncol Clin North Am
Pays: United States
ID NLM: 8709473

Informations de publication

Date de publication:
Dec 2023
Historique:
pubmed: 11 8 2023
medline: 11 8 2023
entrez: 10 8 2023
Statut: ppublish

Résumé

Multiple myeloma is the second most common hematological malignancy with an approximate incidence of up to 8.5 cases per 100,000 persons per year. Over the last decade, therapy for multiple myeloma has undergone a revolutionary change. Chimeric antigen receptor (CAR) T-cell therapy has played a major role in this evolution. In this review, we discuss the existing state of CAR T-cell therapy in myeloma while evaluating several newer therapies and targets expected in the near future.

Identifiants

DOI: 10.1016/j.hoc.2023.05.008 PMID: 37563077
pubmed: 37563077
pii: S0889-8588(23)00063-1
doi: 10.1016/j.hoc.2023.05.008
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1089-1105

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Auteurs

Parth Shah (P)

Department of Hematology, Dartmouth Cancer Center, 1 Medical Center Drive, Lebanon, NH 03750, USA; Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02115, USA. Electronic address: Parth_Shah@DFCI.HARVARD.EDU.

Adam S Sperling (AS)

Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02115, USA; Division of Hematology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.

Classifications MeSH